Press Office
Food and Drug Administration
U.S. Department of Health and Human Services

 

STATEMENT Print Media: 301-827-6242
December 19, 2001 Consumer Inquiries: 888-INFO-FDA

PRE-APPROVAL INSPECTION OF THE BIOPORT FACILITY

This afternoon, the Food and Drug Administration completed the pre-approval inspection of the BioPort facility in Lansing, Mich. An inspection report (FD-483) was issued to the firm, and it contained seven inspectional observations that needed to be addressed. BioPort satisfactorily addressed many of these observations during the inspection.

Based upon the firm's submissions, the observations during the inspection, and pending an adequate response to the inspectional observations, FDA's Center for Biologics Evaluation and Research (CBER) will make a decision on the approvability of the BioPort supplemental Biologics License Application (BLA).

Before new Anthrax Vaccine Adsorbed can be lot released and available for routine shipment, however, FDA must also approve a supplemental BLA for BioPort's contract filling facility, Hollister-Stier Laboratories. A pre-approval inspection of that facility is planned for early January, the earliest date that FDA investigators could observe a filling operation.

# # # #

FDA News Page   |   FDA Home Page 

Office of Public Affairs
Web page created by clb 2001-DEC-19.